Please Wait...

Time to Take Action and Make Risk-Based Monitoring a Reality

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

The current state of RBM and how to implement a successful program are explored in a recent article I authored for the December 2014 edition of EPC (European Pharmaceutical Contractor), entitled Risk-Based Monitoring: A Little More Action. We begin with a look at the EMA definition of quality risk-based management and how it sets the foundation for successful RBM, grounding us in why we're doing RBM in the first place.

European Pharmaceutical ContractorWe also examine the Quality by Design (QbD) process as it provides a clear understanding of your study risks. It's this QbD process that sets you on course to take action and mitigate risks through monitoring. It also enables you to adapt your plans moving forward.

Intelligent risk-based monitoring employs a robust quality process backed by technology to help make sense of the thousands, if not millions, of data points in a trial. To ensure you have the right tools to implement your RBM method, there are some important considerations when evaluating technologies. These include integration ability, data types and sources, KPIs and other factors, all of which are discussed in the article.

One of the major stumbling blocks to RBM I'm seeing with organizations both in the US and Europe is an exhaustive search to find the best monitoring method (when in fact there is no single best method!). While factors like these pose barriers to implementation, the good news many resources are available to help you overcome them so there's no time like the present to get started!

 

Preview Compass Technology

If you'd like to preview BioClinica's RBM-enabling Compass technology, an on-demand webinar is available to watch at your convenience. In it we explore the Intelligent Monitoring approach aimed at raising overall clinical trial quality while reducing risk. I encourage you to watch it if you're having trouble moving your program forward.

In the meanwhile, if you'd like to talk about RBM or need an answer to a specific question, shoot me an email at Courtney.McBean[a]BioClinica.com and I'll walk you through it. I'd love to hear from you about what is, or is not, working for you in your own clinical trials.

Overcoming Barriers to Risk Based Monitoring

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Great advice on imaging in #clinicaltrials! https://t.co/adsP8h99Ic
bioclinica (2 days ago)
https://t.co/UZQTot9ovJ
bioclinica (2 days ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (2 days ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (2 days ago)
RT @eClinical_Jen: Content from the FDA Webinar on Study Data Technical Conformance Guidelines is here: https://t.co/14eepSOR7b #ITTX17
bioclinica (2 days ago)
RT @CenterWatch: .@US_FDA approves first #digital pill with sensor to track #patients adherence, https://t.co/XaEctKIFRx
bioclinica (2 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices